Skip to content

Study · Observational study · 1989

5 results

Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man.

Aitman TJ, Rafferty B, Coy D, Lynch SS, Clayton RN

Peptides1 Jan 1989Cited by 3 (Europe PMC)

PMID2546126 (opens in a new tab)DOI10.1016/0196-9781(89)90065-x (opens in a new tab)PepBankPUB-02546126
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In normal men, peak GH response after subcutaneous GHRH(1-29)NH2 was similar to that after the agonist analogue.

    In plain wordsIn healthy men, GHRH under the skin raised peak growth hormone about as much as the analogue.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak GH response
    Study

    n: not reported in source

    Comparator
    [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    3 micrograms/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Using a submaximal dose of 3 micrograms/kg administered subcutaneously, peak growth hormone (GH) response and area under the GH curve were similar for the native and agonist analogue.
    1 context sentence
    Summary · context
    The bioactivity of growth hormone releasing hormone 1-29 [GHRH(1-29)NH2] has been compared with that of an agonist analogue [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2, in normal male volunteers.
  2. 02HumanObservational studyEfficacy outcome

    In normal men, the area under the GH curve after subcutaneous GHRH(1-29)NH2 was similar to that after the agonist analogue.

    In plain wordsIn healthy men, total growth hormone release after GHRH was similar to that after the analogue.

    Peptide
    Sermorelin
    Outcome
    No significant changeArea under the GH curve
    Study

    n: not reported in source

    Comparator
    [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    3 micrograms/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Using a submaximal dose of 3 micrograms/kg administered subcutaneously, peak growth hormone (GH) response and area under the GH curve were similar for the native and agonist analogue.
    1 context sentence
    Summary · context
    The bioactivity of growth hormone releasing hormone 1-29 [GHRH(1-29)NH2] has been compared with that of an agonist analogue [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2, in normal male volunteers.
  3. 03HumanObservational studyPharmacokinetics

    In normal men, peak GHRH(1-29) immunoreactivity did not differ significantly between the native peptide and the analogue.

    In plain wordsIn healthy men, peak blood levels of GHRH did not differ significantly from those of the analogue.

    Peptide
    Sermorelin
    Outcome
    No significant changePeak GHRH(1-29) immunoreactivity
    Study

    n: not reported in source

    Comparator
    [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 micrograms/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In addition, no significant differences were found in peak GHRH(1-29) immunoreactivity, area under the GHRH(1-29) curves or plasma disappearance rates of the two peptides.
    1 context sentence
    Summary · context
    The bioactivity of growth hormone releasing hormone 1-29 [GHRH(1-29)NH2] has been compared with that of an agonist analogue [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2, in normal male volunteers.
  4. 04HumanObservational studyPharmacokinetics

    In normal men, the area under the GHRH(1-29) curve did not differ significantly between the native peptide and the analogue.

    In plain wordsIn healthy men, total GHRH exposure did not differ significantly from that of the analogue.

    Peptide
    Sermorelin
    Outcome
    No significant changeArea under the GHRH(1-29) curve
    Study

    n: not reported in source

    Comparator
    [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 micrograms/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In addition, no significant differences were found in peak GHRH(1-29) immunoreactivity, area under the GHRH(1-29) curves or plasma disappearance rates of the two peptides.
    1 context sentence
    Summary · context
    The bioactivity of growth hormone releasing hormone 1-29 [GHRH(1-29)NH2] has been compared with that of an agonist analogue [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2, in normal male volunteers.
  5. 05HumanObservational studyPharmacokinetics

    In normal men, the plasma disappearance rate of GHRH(1-29) did not differ significantly from that of the analogue.

    In plain wordsIn healthy men, GHRH cleared from blood at a rate not significantly different from the analogue.

    Peptide
    Sermorelin
    Outcome
    No significant changePlasma disappearance rate
    Study

    n: not reported in source

    Comparator
    [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    3 micrograms/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In addition, no significant differences were found in peak GHRH(1-29) immunoreactivity, area under the GHRH(1-29) curves or plasma disappearance rates of the two peptides.
    1 context sentence
    Summary · context
    The bioactivity of growth hormone releasing hormone 1-29 [GHRH(1-29)NH2] has been compared with that of an agonist analogue [Ac-D-Tyr1,D-Ala2]-GHRH(1-29)NH2, in normal male volunteers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.